| Code | CSB-RA015007MB15HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to B-001, targeting MS4A1 (Membrane Spanning 4-Domains A1), also known as CD20. MS4A1 is a B-cell surface antigen expressed during B lymphocyte development from the pre-B cell stage through mature B cells, but absent on plasma cells. This transmembrane phosphoprotein plays a crucial role in regulating B-cell activation, proliferation, and differentiation through calcium ion channel activity. MS4A1 is critically implicated in various B-cell malignancies including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and B-cell acute lymphoblastic leukemia, as well as autoimmune disorders such as rheumatoid arthritis and multiple sclerosis.
B-001 (rituximab) is a well-established therapeutic antibody that binds to the MS4A1 antigen, inducing B-cell depletion through complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and direct apoptosis. This biosimilar antibody serves as a valuable research tool for investigating B-cell biology, immune regulation mechanisms, and therapeutic target validation in oncology and autoimmune disease studies.
There are currently no reviews for this product.